A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer
Introduction: Small cell prostate cancer (SCPC) is a rare histologic subtype of prostate cancer, for which the optimal staging strategy remains unclear. Method: The Surveillance, Epidemiology, and End Results database was used to analyze the incidence and outcomes of SCPC between the years 2004 through 2016. Limited-stage SCPC (LS-SCPC) was defined as SCPC without any metastasis regardless of local invasion. Extensive stage SCPC (ES-SCPC) was defined as any metastasis to lymph nodes and/or to distant organs. Result: A total of 403 SCPC patients were included in the study cohort, accounting for 0.056% of all prostate cancer cases (n=719,655). Of the 358 patients with known metastasis status, 275 (76.8%) patients had ES-SCPC, whereas 83 (23.2%) patients had LS-SCPC. LS-SCPC was associated with better overall survival (17 vs. 9 mo, P
ConclusionChronic inflammation in the dorsolateral prostate of rats dosed with EB, T and E resulted in deregulated expression in a set of microRNAs whose target genes were related to tumor growth or abnormal proliferation. Our findings suggest the identified microRNAs and their target genes the potential use as biomarkers to predict prostate cancer development. Validation using human samples is warranted.
Condition: Prostate Adenocarcinoma Interventions: Other: Hyperpolarized Carbon C 13 Pyruvate; Procedure: Magnetic Resonance Spectroscopic Imaging; Procedure: Surgical Procedure Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Authors: Chatrabnous N, Jafarzadeh A, Ghaderi A, Ariafar A, Aminizadeh N, Ghassabi F, Nemati M Abstract BACKGROUND: Inflammation has a prominent role in cancer development and interleukin (IL)-33 has both inflammatory and anti-inflammatory properties. The aim of this study was to measure IL-33 quantities and genetic alterations in the rs1929992 SNP within IL-33 gene in patients with prostate cancer (PC). METHODS: This investigation was conducted on blood specimens from 150 newly diagnosed PC patients and 150 healthy age-matched controls. Serum IL-33 measurements and genotyping were performed by ELISA and PCR-RF...
The adrenal-permissive HSD3B1 genotype is associated with worse clinical outcomes in men with metastatic castration-sensitive prostate cancer, according to an analysis of data from a clinical trial.Reuters Health Information
Conclusions: This series suggests the use of antiplatelet or anticoagulant medication is not an absolute contraindication to fiducial marker placement in patients undergoing SBRT or IGRT for prostate cancer. These patients should be closely monitored after the procedure for bleeding complications. Practitioners may consider the patient's medical comorbidities, risk factors for thromboembolism, and overall functional status as there is no standardized protocol for discontinuing anticoagulant or antiplatelet therapy for fiducial marker placement.
Conclusions: Cholecystectomy is associated with an increased hazard ratio of prostate cancer in gallstones patients, and the risk increases with an incremental period of follow-up. This observational study cannot ascertain the detrimental mechanisms of cholecystectomy for the development of prostate cancer, and cholecystectomy is not recommended for the prevention of prostate cancer based on our study.
Conditions: Prostate Adenocarcinoma; Lower Urinary Tract Symptoms Intervention: Combination Product: Bicalutamide implant Sponsor: Alessa Therapeutics Inc. Not yet recruiting
CONCLUSION: Patients who were exposed to asbestos should possibly be encouraged to complete more frequent prostate cancer screening. PMID: 32097115 [PubMed - as supplied by publisher]
Publication date: Available online 25 February 2020Source: European UrologyAuthor(s): Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, Alberto Briganti